The role of new agents in the treatment of colorectal cancer

Oncology

Volumn 66, Issue 1, 2004, Pages 1-17

  Folprecht, Gunnar ^a   Köhne, Claus Henning ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Capecitabine; Cetuximab; Chemotherapy; Colorectal cancer; Irinotecan; Oxaliplatin; UFT

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 5 ETHYNYLURACIL; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANERTINIB; CAPECITABINE; CELECOXIB; CETUXIMAB; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PELITINIB; PROTEIN TYROSINE KINASE INHIBITOR; ROFECOXIB; SEMAXANIB; TEGAFUR; THYMIDYLATE SYNTHASE INHIBITOR; UFT; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR; VATALANIB; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG DERIVATIVE; PLATINUM COMPLEX; URACIL;

ACNE; ADENOMATOUS POLYP; CARDIOTOXICITY; CEREBROVASCULAR DISEASE; CHOLINERGIC SYSTEM; CLINICAL TRIAL; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOXICITY; ELECTROLYTE DISTURBANCE; FOLLICULITIS; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HEART INFARCTION; HUMAN; KIDNEY DISEASE; LIVER METASTASIS; LUNG EMBOLISM; LUNG METASTASIS; MUSCLE CRAMP; NEUROTOXICITY; NEUTROPENIA; PALLIATIVE THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZATION; RASH; REVIEW; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; HUMANS; ORGANOPLATINUM COMPOUNDS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TEGAFUR; TREATMENT OUTCOME; URACIL;

EID: 1642525642     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076329     Document Type: Review

References (117)

1. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992;10:896-903.
2. Piedbois P, Michiels S, Meta-Analysis Group in Cancer: Survival benefit of 5FU/LV over 5FU bolus in patients with advanced colorectal cancer: An updated meta-analysis based on 2,751 patients. Proc Am Soc Clin Oncol, in press.
3. Rothenberg M, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 2001;19:3801-3807.
4. Liu G, Franssen E, Fitch MI, Warner E: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-115.
5. Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, van der BK, Wanders J, de Boer RF, Martin C, Fumoleau P: Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: A randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002;38:349-358.
6. Hoff PM, Pazdur R, Benner SE, Canetta R: UFT and leucovorin: A review of its clinical development and therapeutic potential in the oral treatment of cancer. Anticancer Drugs 1998;9:479-490.
7. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-1281.
8. Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, Reigner B, Griffin T, Kaye S, Verweij J: Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 1998;16:2977-2985.
9. Van Cutsem E, Findlay M, Osterwalder B, Kocha W, Dalley D, Pazdur R, Cassidy J, Dirix L, Twelves C, Allman D, Seitz JF, Scholmerich J, Burger HU, Verweij J: Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study. J Clin Oncol 2000;18:1337-1345.
10. Schilsky RL, Levin J, West WH, Wong A, Colwell B, Thirlwell MP, Ansari RH, Bell WN, White RL, Yates BB, McGuirt PV, Pazdur R: Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. J Clin Oncol 2002;20:1519-1526.
11. Van Cutsem E, Sorensen J, Cassidy J, Daniel F, Harper P, Bailey N, Peachey M, Sommerville M: International phase III study of oral eniluracil (EU) plus 5-fluorouracil (5-FU) versus intravenous (IV) 5-FU plus leucovorin (LV) in the treatment of advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol 2001;20:131a.
12. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 2001;19:4097-4106.
13. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001;19:2282-2292.
14. Carmichael J, Popiela T, Radstone D, Falk S, Borner M, Oza A, Skovsgaard T, Munier S, Martin C: Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20:3617-3627.
15. Douillard JY, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P, Vincent MD, Lembersky BC, Thompson S, Maniero A, Benner SE: Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20:3605-3616.
16. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, François E, Bedenne L: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 1997;15:808-815.
17. Weh HJ, Zschaber R, Braumann D, Hoelzer D, Hoffman R, Becker K, Kleeberg U, Pompecki R, Hoffkracht M, Benner A, Hossfeld D: A randomized phase III study comparing weekly folinic acid (FA) and high dose 5-fluorouracil (5-FU) with monthly 5-FU/FA (days 1-5) in untreated patients with metastatic colorectal carcinoma. Onkologie 1998;21:403-407.
18. Köhne CH, Wils J, Lorenz M, Schöffski P, Voigtmann R, Bokemeyer C, Lutz M, Kleeberg U, Ridwelski K, Souchon R, El-Serafi M, Wei U, Burkhard O, Rückle H, Lichinitser M, Langenbuch T, Slangendijk R, Cheithauer W, Baron B, Couvreur ML, Schmoll HJ: Randomized phase III study of high dose 5-fluorouracil given as a weekly 24 hour infusion with or without leucovorin vs. bolus 5-fluorouracil plus leucovorin in advanced colorectal cancer. J Clin Oncol, in press.
19. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
20. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKendric J, Maroun J, Marshall J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schilsky RL: First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002;13:566-575.
21. Bertolini A, Flumano M, Fusco O, Muffatti A, Scarinci A, Pontiggia G, Scopelliti M: Acute cardiotoxicity during capecitabine treatment: A case report. Tumori 2001;87:200-206.
22. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-1418.
23. Rougier P, Van CE, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-1412.
24. Rougier P, Van CE, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-1412.
25. Ulrich-Pur H, Kornek GV, Fiebiger W, Gedlicka C, Raderer M, Lenauer A, Depisch D, Lang F, Pidlich J, Scheithauer W: Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy. Ann Oncol 2001;12:1269-1272.
26. Von Hoff DD, Rothenberg ML, Pitot HC, Elfring GL, Mohrland JS, Schaaf LJ, Neff LL, Locker PK, Gibson RE, Miller LL: Irinotecan (CPT-11) therapy for patients with previously treated metastatic colorectal cancer (CRC): Overall results of FDA-reviewed pivotal US clinical trials. Proc Am Soc Clin Oncol 1997;16:228a.
27. Van Cutsem E, Rougier P, Droz JP, Marty M, Bleiberg H: Clinical benefit of irinotecan (CPT-11) in metastatic colorectal cancer (CRC) resistant to 5-FU. Proc Am Soc Clin Oncol 1997;16:268a.
28. Fuchs CS, Hecht JR, Moore MR, Harker G, Rinaldi DA, Villa L, McGovern JP: Phase III comparison of two CPT-11 dosing regimens (weekly !4 every 6 weeks vs. every 3-weeks) in second-line metastatic colorectal cancer (MCRC) therapy. Proc Am Soc Clin Oncol 2002;21:129a.
29. André T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, Lotz JP, Gilles-Amar V, Krulik M, Carola E, Izrael V, de Gramont A: CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999;35:1343-1347.
30. Tournigand C, Louvet C, Quinaux E, André T, Lledo G, Flesh M, Ganem G, Landi B, Colin F, Denet C, Mery-Mignard D, Risse M, Buyse M, de Grammont A: FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): Final results of a phase III study. Proc Am Soc Clin Oncol 2001;20:124a.
31. Köhne CH, Van Cutsem E, Wils J, Bokemeyer C, El-Sarafi M, Lutz M, Lorenz M, Reichardt P, Rückle-Lanz H, Frickhofen N, Fuchs R, Mergenthaler H-G, Langenbuch T, Vandebroeck A, Douillard J-Y, Vanhoefer U, Voigtmann R, Mitry E, Müller L, Baron B, Vanacker NG, Nordlinger B: Weekly high dose infusional 5-FU plus folinic acid (FA) with or without irinotecan (IRI) in metastatic colorectal cancer (MCRC): Interim safety results of EORTC study 40986. Proc Am Soc Clin Oncol 2002;21:134a.
32. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000;355:1041-1047.
33. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
34. Miller L, Emanuel D, Elfring GL, Barker K, Saltz L: 60-day, all-cause mortality with firstline irinotecan/fluorouracil/leucovorin (IFL) or fluorouracil/leucovorin (FL) for metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2002;21:129a.
35. Van Cutsem E, Douillard JY, Köhne CH: 5-Fluorouracil/leukovorin/ irinotecan scheduling in colorectal cancer. N Engl J Med 2001;345:1351.
36. Van Cutsem E, Cunningham D, Bokkel Huinink WW, Punt CJ, Alexopoulos CG, Dirix L, Symann M, Blijham GH, Cholet P, Fillet G, Van Groeningen C, Vannetzel JM, Levi F, Panagos G, Unger C, Wils J, Cote C, Blanc C, Herait P, Bleiberg H: Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur J Cancer 1999;35:54-59.
37. Cascinu S, Fedeli A, Fedeli SL, Catalano G: Control of chemotherapy-induced diarrhoea with octreotide in patients receiving 5-fluorouracil. Eur J Cancer 1992;28:482-483.
38. Lenfers BH, Loeffler TM, Droege CM, Hausamen TU: Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment. Ann Oncol 1999;10:1251-1253.
39. Diaz-Rubio E, Sastre J, Zaniboni A, Labianca R, Cortes-Funes H, de Braud F, Boni C, Benavides M, Dallavalles G, Homerin M: Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric trial. Ann Oncol 1998;9:105-108.
40. Zori CA, Blajman C, Richardet E, Bella S, Vilanova M, Coppola F, Van Kooten M, Rodger J, Giglio R, Balbiani L, Perazzo F, Montiel M, Chacon M, Pujol F, Mickiewicz E, Cazap E, Recondo G, Lastiri F, Simon J, Wasserman E, Schmilovich A: A randomised phase II sudy of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. Eur J Cancer 2001;37:1006-1013.
41. Machover D, Diaz Rubio E, de Gramont A, Schilf A, Gastiaburu JJ, Brienza S, Itzhaki M, Metzger G, N'Daw D, Vignoud J, Abad A, François E, Gamelin E, Marty M, Sastre J, Seitz JF, Ychou M: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996;7:95-98.
42. Raymond E, Buquet-Fagot C, Djelloul S, Mester J, Cvitkovic E, Allain P, Louvet C, Gespach C: Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 1997;8:876-885.
43. Rothenberg ML, Oza AM, Burger B, Berlin J, Marshall J, Ramanathan RK, Gupta S, Garay C, Haller DG: Phase III trial of bolus + infusional 5-FU/leucovorin vs. oxaliplatin vs. the combination in patients with recurrent metastatic colorectal cancer following irinotecan, bolus 5-FU, and leucovorin: Interim results. Ann Oncol 2002;13:2.
44. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as firstline treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
45. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-147.
46. Grothey A, Deschler B, Kroening H, Ridwelski K, Reichardt P, Kretzschmar A, Clemens M, Hirschmann W, Lorenz M, Asperger W, Buechele T, Schmoll HJ: Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs. weekly high-dose 24 h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002;21:129a.
47. Goldberg RM, Morton RF, Sargent DJ, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP: N9741: Oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI Intergroup study. Proc Am Soc Clin Oncol 2002;21:128a.
48. Wasserman E, Kalla S, Misset JL, Goldwasser F, Bedairia N, Bensamine MA, Marty M, Cvitkovic E: Oxaliplatin (L-OHP) and irinotecan (CPT11) phase I/II studies: Results in 5 FU refractory (FR) colorectal cancer (CRC) patients (pts). Proc Am Soc Clin Oncol 1999;18:238a.
49. Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, Brienza S, Alafaci E, Bertheault-Cvitkovic F, Jasmin C, Reynes M, Bismuth H, Misset JL, Levi F: Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 4-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999;10:663-669.
50. Gil-Delgado M, Bastian G, Guinet F, Antoine E, Cajfinger FL, Rocher MA, Coeffic D, Spano JP, Taillibert S, Bismuth H, Khayat D: Final results of oxaliplatin (LOHP) + irinotecan (CPT11) and FU-FOL (LV5 FU2) combination and pharmacokinetic (PK) analysis in advanced colorectal cancer (ACRC) patients (pts). Proc Am Soc Clin Oncol 2001;20:140a.
51. Ychou M, Nordlinger B, Quenet F, Rivoire ML, Desseigne F, Négrier S, Rougier P, Giovannini M, Delpero JR, Houvenaeghel G, Bugat R, Delord JP, Lazorthes F, Couteau C, Ferment O, Chaboisseau E: CPT-11/L-OHP/5-FU/LV combination before liver surgery in patients with not optimally resectable colorectal cancer liver metastases: Methodology and preliminary results, phase II study. Proc Am Soc Clin Oncol 2002;21:162a.
52. Knight RD, Miller LL, Pirotta N, Elfring GL, Locker P, Saltz L: First line irinotecan (C), fluorouracil (F), leukovorin (L) especially improves survival (OS) in metastatic colorectal cancer (MCRC) patients (PT) with favorable prognostic indicators. Proc Am Soc Clin Oncol 2000;19:254a.
53. Köhne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schoffski P, Micheel S, Hecker H: Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: Results of a multivariate analysis of 3,825 patients. Ann Oncol 2002;13:308-317.
54. Rougier P, Lepille D, Douillard JY, Marrero AM, Ducreux M, Mignot L, Hua A: Final results of a randomised phase II study of three combinations: CPT-11 + LV5FU2, LOHP + LV5FU2, and CPT-11 + LOHP in 5-FU resistant advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2001;20:142a.
55. Becouarn Y, Gamelin E, Coudert B, Négrier S, Pierga JY, Raoul JL, Provençal J, Rixe O, Krisch C, Germa C, Bekradda M, Mignard D, Mousseau M: Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients. J Clin Oncol 2001;19:4195-4201.
56. Tabernero J, Butts AC, Cassidy J, Conroy T, de Braud F, Diaz-Rubio E, Figer A, Schoeffski P, Grossmann J, Sobrero A, Twelves C, Van Cutsem E: Capecitabine and oxaliplatin in combination (Xelox) as first line therapy for patients (pts) with metastatic colorectal cancer (MCRC): Results of an international multicenter phase II trial. Proc Am Soc Clin Oncol 2002;21:133a.
57. Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, Herrmann R, Pestalozzi BC, Saletti P, Hanselmann S, Muller S, Brauchli P, Castiglione-Gertsch M, Goldhirsch A, Roth AD: Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002;20:1759-1766.
58. Schleucher N, Tewes M, Achterrath W, Hense J, Omidi S, Frings S, Rustum YM, Harstrick A, Seeber S, Vanhoefer U: Extended phase I study of capecitabine in combination with a weekly schedule of irinotecan as first-line chemotherapy in metastatic colorectal cancer. Proc Am Soc Clin Oncol 2001;20:141a.
59. Kerr DJ, ten Bokkel Huinink WW, Ferry D, Rea DW, Boussard BM, Oulid-Aissa D, Frings S, Nortier JW: A phase I/II study of CPT-11 in combination with capecitabine as first line chemotherapy for metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2002;21:161a.
60. Jordan K, Grothey A, Kellner O, Constantin C, Dietrich G, Schlichting C, Mantovani L, Kroening H, Hagen V, Gutberlet K, Forstbauer H, Schmoll HJ: Randomized phase II trial of capecitabine plus irinotecan vs. capecitabine plus oxaliplatin as first-line therapy in advanced colorectal cancer (ACRC): Results of an interim analysis. Proc Am Soc Clin Oncol 2002;21:103b.
61. 2 (A), or an individual dose optimisation (B) or a risk factor optimisation (C) in patients (Pts) with metastatic colorectal cancer (Mcrc) previously Tr. Proc Am Soc Clin Oncol 2000;19:244a.
62. Merrouche Y, Extra JM, Abigerges D, Bugat R, Catimel G, Suc E, Marty M, Herait P, Mahjoubi M, Armand JP: High-dose intensity of irinotecan administered every 3 weeks in advanced cancer patients: A feasibility study. J Clin Oncol 1997;15:1080-1086.
63. Ychou M, Kramar A, Raoul JL, Desseigne F, Hua A, Vernillet L, Merrouche Y: Final results of a phase II study using CPT-11 high dose (500 MG/M2) as first line chemotherapy in patients with metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2001;20:249a.
64. Ducreux M, Marti P, Raoul JL, Merrouche Y, Risse M-L, Mery-Mignard D, Boige V: Phase II study of high-dose irinotecan (CPT11) combined with 5 fluorouracil/folinic acid (LV5-FU2) in 1st line metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2002;21:160a.
65. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, François E, Bedenne L: A randomized trial comparing monthly low-dose leucovorin/fluorouracil bolus with bimonthly high-dose leucovorin/fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 1997;15:808-815.
66. Masi G, Allegrini G, Danesi R, di Paolo A, Cupini S, Marcucci L, Pfanner E, Brunetti I, Conte PF, Del Tacca M, Falcone A: Bi-weekly irinotecan (CPT-11), oxaliplatin (LOHP), leucovorin (LV) and 5-fluorouracil (5-FU) 48 h. continuous infusion in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002;21:169a.
67. Souglakos J, Mavroudis D, Kakolyris S, Kourousis C, Vardakis N, Androulakis N, Agelaki S, Kalbakis K, Tsetis D, Athanasiadis N, Samonis G, Georgoulias V: Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: A multicenter phase II trial. J Clin Oncol 2002;20:2651-2657.
68. Aschele C, Friso ML, Pucciarelli S, Sartor L, Lonardi S, De Salvo G, Fabris G, da Dalt G, Ranzato R, Bruttocao A, Neri D, Finco C, Monfardini S: A phase I-II study of weekly oxaliplatin (OXA), 5-fluorouracil (FU) continuous infusion (CI) and preoperative radiotherapy (RT) in locally advanced rectal cancer (LARC). Proc Am Soc Clin Oncol 2002;21:132a.
69. Ehrlichman C, Goldberg RM, Sloan JA, Reid JM, Adjei AA, Atherton P, Windebank AJ, Hanson LJ: Phase I study of the combination of CPT-11/5FU/leucovorin/oxaliplatin. Proc Am Soc Clin Oncol 2002;21:107a.
70. Roth AD, Seium Y, Ruhstaller T, Bauer J, Soravia C, Mentha G, Trembleau C, Morant R, Stupp R: Oxaliplatine (OXA) combined with irinotecan (CPT-11) and 5FU/leucovorin (OCFL) in metastatic colorectal cancer (MCRC): A phase I-II study. Proc Am Soc Clin Oncol 2002;21:143a.
71. Calvo E, Cortes JE, Rodriguez J, Rebollo J, Martin-Algarra S, Garcia-Foncillas J, Salgado E, Gonzalez-Cao M, Aramendia JM, Fernandez-Hidalgo O, Brugarolas A: Irinotecan, oxaliplatin plus 5-FU/leucovorin in advanced colorectal cancer. Proc Am Soc Clin Oncol 2001;20:136a.
72. Lerebours F, Cottu P, Hocini H, Bedairia N, Bexon A, Chouaki N, Espie M, Marty M: Oxaliplatin (OXA), irinotecan (CPT11), and 4-day continuous infusion 5-fluorouracil (CIVFU) every three weeks (Q3W): A phase I study in advanced gastrointestinal tumors. Proc Am Soc Clin Oncol 2000;19:313a.
73. Rubio G, Chacon M, Coppola F, Martinez J, Hidalgo J, Richardet E, Carranza L, Sena S, Vera K, Martin C, Wasserman E: CPT-11/oxaliplatin (OXA) plus folinic acid (FA)/5-FU bolus (triple combination): An active and feasible combination in metastatic colorectal cancer (CRC) patients (pts). Proc Am Soc Clin Oncol 2002;21:110b.
74. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-1188.
75. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T: Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995;55:3785-3789.
76. DuBois RN, Smalley WE: Cyclooxygenase, NSAIDs, and colorectal cancer. J Gastroenterol 1996;31:898-906.
77. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA: The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000;60:5040-5044.
78. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, Beauchamp RD, DuBois RN: Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997;99:2254-2259.
79. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952.
80. Lundholm K, Gelin J, Hyltander A, Lonnroth C, Sandstrom R, Svaninger G, Korner U, Gulich M, Karrefors I, Norli B: Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 1994;54:5602-5606.
81. Lin E, Morris J, Chau NK, Crane C, Wolff R, Janjan N, Xiong H, Delcos M, Abbruzzese JL: Celecoxib attenuated capecitabine induced hand-and-foot syndrome (HFS) and diarrhea and improved time to tumor progression in metastatic colorectal cancer. Proc Am Soc Clin Oncol 2002;21:138b.
82. Blanke CD, Benson A, Dragovich T, Lenz H-J, Haller D, Robles C, Buchbinder A: A phase II trial of celecoxib (CX), irinotecan (I), 5-fluorouracil (5FU), and leucovorin (LCV) in patients (pts) with unresectable or metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 2002;21:127a.
83. Nicholson RI, Gee JM, Harper ME: EGFR and cancer prognosis. Eur J Cancer 2001;37:(suppl 4):S9-S15.
84. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J, Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995;1:1311-1318.
85. Saltz L, Rubin M, Hochster H, Tchemeydian NS, Waksal HW, Needle M, LoBuglio A: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR): Proc Am Soc Clin Oncol 2001;20:3a.
86. Saltz L, Meropol NJ, Loehrer PJ, Waksal HW, Needle M, Mayer RJ: Single agent IMC-C225 (Erbitux) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2002;21:127a.
87. Rosenberg AH, Loehrer PJ, Needle M, Waksal HW, Hollywood E, Ramos L, Saltz LB: Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr). Proc Am Soc Clin Oncol 2002;21:135a.
88. Lutz MP, Schöffski P, Folprecht G, Haag C, Seufferlein T, Beutel G, Marschner JP, Mueser M, Harstrick A, Köhne CH: A phase I/II study of cetuximab (C225) plus irinotecan (CPT-11) and 24 h infusional 5FU/folinic acid (FA) in the treatment of metastatic colorectal cancer (MCRC) expressing the epidermal growth factor receptor (EGFR). Ann Oncol 2002;13:73.
89. Hammond L, Figueroa L, Schwartzberg LS, Ochoa L, Hidalgo M, Olivio N, Schwartz G, Smith L, Ochs J, Rowinsky EK: Feasibility and pharmacocinetic (PK) trial of ZD1839 (Iressa™), an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 2001;20:137a.
90. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman DC: Phase I safety and pharmacokinetic study of recombinant human antivascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-850.
91. Bergsland E, Hurwitz H, Fehrenbacher L, Meropol NJ, Novotny L, Gaudreault J, Lieberman G, Kabbinavar F: A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2000;19:242a.
92. Giantonio B, Levy D, Catalano PJ, O'Dwyer PJ, Benson A: Incorporating angiogenesis inhibition with bevacizumab (anti-VEGF) into frontline chemotherapy with irinotecan (CPT-11), fluorouracil and leukovorin (FU/LV) for advanced colorectal cancer (advCRC): A toxicity analysis of ECOG study E2200. Proc Am Soc Clin Oncol 2002;21:126a.
93. Rougier P, Van CE, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-1412.
94. Van Cutsem E, Douillard J-.Y, Köhne CH: Toxicity of irinotecan in patients with colorectal cancer. N Engl J Med 2001;345:1351-1352.
95. Maindrault-Goebel F, Louvet C, André T, Carola E, Lotz JP, Molitor JL, Garcia ML, Gilles-Amar V, Izrael V, Krulik M, de Gramont A: Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). Eur J Cancer 2000;35:1338-1342.
96. Grothey A, Jordan K, Kellner O, Constantin C, Dietrich G, Kroening H, Mantovani L, Schlichting C, Forstbauer H, Schmoll HJ: Randomized phase II trial of capecitabine plus irinotecan vs. capecitabine plus oxaliplatin as first-line therapy of advanced colorectal cancer (ACRC). Ann Oncol 2002;13:71.
97. Cassata A, Stani SC, Alu M, Procopio G, Cortinovis D, Beretta E, Ferrario E, Longarini R, Baldini A, Lambiase A, Di Bartolomeo M, Buzzoni R, Bidoli P, Bajetta E: Ongoing phase II trial with two schedules of irinotecan (CPT-11) in combination with capecitabine as first line chemotherapy in patients with advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2001;20:144a.
98. Schields AF, Zalupski MM, Marschall JL, Meropol NJ: A phase II trial of oxaliplatin and capecitabine in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 2002;21:143a.
99. Scheithauer W, Kornek GV, Raderer M, Schull B, Schmid K, Langle F, Huber H: Intermittent weekly high-dose capecitabine in combination with oxaliplatin: A phase I/II study in first-line treatment of patients with advanced colorectal cancer. Ann Oncol 2002;13:1583-1589.
100. Escudero P, Alonso V, Puertolas T, Alvarez I, Corral M, Herrero A, Andres R, Martinez-Trufero J, Filipovich E, Grandez R, Artal A, Anton A, Tres A, Polo E: Weekly irinotecan (CPT-11) combined with UFT as first line treatment of advanced colorectal carcinoma (ACRC). Proc Am Soc Clin Oncol 2002;21:106b.
101. Cruz JJ, Méndez M, Pujol E, Belón J, Cerezuela P: Weekly irinotecan (CPT-11) in combination with oral uracil and ftorafur (UFT) plus folinic acid (FA) as first line treatment in advanced colorectal cancer (CRC). Preliminary results. Proc Am Soc Clin Oncol 2001;20:109b.
102. Alonso V, Escudero P, Zorrilla M, Isla MD, Herrero A, Mayordomo JI, Martinez-Trufero J, Saenz A, Tres A, Anton A: Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer. Eur J Cancer 2001;37:2385-2391.
103. Garcia-Girón C, Feliu J, Vincent JM, Madronal C, Fonseca E, Constela M, de las Heras B, Camps C, Dorta J, Iglesias J, Castro J, Lorenzo J, González-Barón M: Phase II trial of oxaliplatin-Uft-leucovorin (OXA-UFTLV) combination in first line treatment of advanced colorectal cancer (ACC). Proc ASCO 2000;19:293a.
104. Delord JP, Pierga JY, Dieras V, Bertheault-Cvitkovic F, Turpin FL, Lokiec F, Canal P, Chatelut E, Guimbaud R, Cornen X, Mouri Z, Bugat R: Dose escalation and pharmacokinetic study of capecitabine (Xeloda) and irinotecan (CPT-11) in gastro-intestinal tumors: Preliminary results. Proc Am Soc Clin Oncol 2002;21:100a.
105. Hirawat S, Kolitz J, Lichtman S, Allen SL, Villani G, Gonzalez A, Fricano M, Budman DR, Shore N: Sequential irinotecan and capecitabine (Xeloda) given every other week in the management of advanced metastatic carcinoma: A phase I study. Proc Am Soc Clin Oncol 2002;21:79b.
106. Diaz-Rubio E, Evans TRJ, Tabernero J, Cassidy J, Sastre J, Eatock M, Bisset D, Regueiro P, Baselga J: Capecitabine [Xeloda(R)] in combination with oxaliplatin: A phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Ann Oncol 2002;13:558-565.
107. Zeuli M, Costanzo ED, Sdrobolini A, Gasperoni S, Paoloni FP, Carpi A, Moscetti L, Cherubini R, Cognetti F: Capecitabine and oxaliplatin in advanced colorectal cancer: A dose-finding study. Ann Oncol 2001;12:1737-1741.
108. Garcia AA, Lenz H-J, Groshen DR, Lara PN, Gumerlock P, Shibata S, Doroshow JH, Synold T, Newman E: Phase I study of oxaliplatin (OX) in combination with capecitabine (C) in metastatic or recurrent solid tumors: A California Consortium trial. Proc Am Soc Clin Oncol 2002;21:82b.
109. Thomas RR, Quinn MG, Wilson RH, Floeter MK, Lehky T, Saif MW, Hamilton JM, Monahan B, Grochow L, Harold N, Schuler B, Allegra C, Cliatt J, Grem JL: A phase I trial of capecitabine (CAPE) and oxaliplatin (OHP). Proc Am Soc Clin Oncol 2001;20:133a.
110. Redlinger M, Stevenson JP, Raskay BJ, Haller D, Sun W, Algazy K, Giantonio B, O'Dwyer PJ: Phase I trial of irinotecan (CPT-11) in combination with oral UFT and leucovorin (LV) in patients with advanced malignancies. Proc Am Soc Clin Oncol 2001;20:94b.
111. Castellano D, Gravalos C, Garcia-Alfonso P, Martin B, Pérez-Manga G, Cortés-Funes H, Pronk L: Phase I/II study of escalating doses of irinotecan (CPT-11) in combination with UFT/folinic acid (FA) in patients (pts) with advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 2001;20:145a.
112. Hill M, Twelves C, Cunningham D, Glasspool R, Price T, Macham MA, Massey A, Jeynes A, MacKay H: A phase I/II study of oral uracil/tegafur (UFT) plus leucovorin (LV) combined with irinotecan (CPT-11) in patients with advanced or metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 2000;19:258a.
113. Sadahiro S, Suzuki T, Ishikawa K, Tajima T, Makuuchi H: Phase I/II studies of 24-hour irinotecan (CPT-11) continuous infusion and oral therapy with uracil/tegafur (UFT) for metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2002;21:97b.
114. Voravud N: A phase I study of oxaliplatin (oxa) in combination with UFT (uracil, tegafur) and OFA (oral folinic acid) in the treatment of advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002;21:124b.
115. Douillard J-Y, Seitz JF: A phase I study of oral uracil/tegafur (UFT) plus leucovorin (LV) combined with oxaliplatin in patients with metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 2001;20:144a.
116. Hurwitz H, Fehrenbacher L, Cartwright T, Hainsworth J, Heim W, Berlin J, Griffing S, Novotny W, Holmgren E, Kabbinavar F: Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. ASCO meeting, May 2003, abstract 3646. http://www.asco.org/hurwitz_no3646.
117. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Van Cutsem E: Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2003;22:252.